Welcome back to Peptides for Women podcast!
In this episode, I’m joined by Dustin Robinson, founding partner of LumaLex Law, an attorney, CPA, and entrepreneur who works with companies in emerging and highly regulated industries. We’re talking about the legal and regulatory side of the peptide industry, including research-use peptides, compounding pharmacies, telehealth, social media, and what doctors and consumers should understand as the industry continues to evolve.
Dustin shares why peptides, psychedelics, cannabis, healthcare, and other industries can be so complicated from a legal perspective. We also talk about the differences between research-use-only (RUO) products and regulated compounding pharmacies, how state and federal regulations can overlap, and why the laws surrounding peptides can change so quickly.
We also get into the recent discussions around peptides being considered for the 503A bulk drug list, what that could mean for access, the future of peptide supply chains, and why the demand for peptides could create new challenges for pharmacies and API manufacturers.
Finally, Dustin explains some of the legal risks around affiliate marketing and social media, including why peptide companies and influencers need to be careful about what they say online and how Meta handles content related to regulated industries.
In this episode, we cover:
Why emerging industries like peptides, psychedelics, cannabis, and healthcare have complicated legal frameworks
How Dustin’s firm uses AI and legal technology to keep up with changing regulations
Corporate practice of medicine (CPOM) and why telehealth companies need to understand state-specific laws
How MSO-PC structures work and why they can be different from state to state
The difference between 503A compounding pharmacies and RUO products
Why an RUO product is not the same thing as a prescription
The legal risks doctors may face when using RUO products with patients
Why some peptides have been difficult to compound through 503A pharmacies
The recent PCAC discussions around several peptides and what could happen next
FDA rulemaking and the idea of “enforcement discretion”
Why peptide demand could potentially outpace the regulated supply chain
Where peptide APIs come from and the difference between regulated and unregulated supply chains
Certificates of Analysis (COAs) and why independent batch testing matters
The legal risks of affiliate marketing for RUO companies
Why companies can be responsible for claims made by their affiliates
Social media, Meta, and why peptide and other regulated-industry accounts can be removed
Why educational content may be safer than promoting personal use
Dustin’s thoughts on AI and how it is changing businesses and law firms
What the future could look like as AI becomes more integrated into everyday life
Connect with Dustin Robinson!
Links & Resources:
‼️Disclaimer‼️
This podcast is for informational purposes only and does not provide medical advice. Always speak with your licensed healthcare provider before starting or changing any medication or treatment plan.
